Results 91 to 100 of about 8,186 (190)

Biology of CD1- and MR1-Restricted T Cells

open access: yesAnnual Review of Immunology, 2014
Over the past 15 years, investigators have shown that T lymphocytes can recognize not only peptides in the context of MHC class I and class II molecules but also foreign and self-lipids in association with the nonclassical MHC class I–like molecules, CD1 proteins. In this review, we describe the most recent events in the field, with particular emphasis
Salio, M   +3 more
openaire   +2 more sources

MR1- and HLA-E-Dependent Antigen Presentation of Mycobacterium tuberculosis

open access: yes, 2022
MR1 and HLA-E are highly conserved nonclassical antigen-presenting molecules. They can present antigens derived from Mycobacterium tuberculosis to a distinct subset of MR1-restricted or HLA-restricted CD8+ T cells.
Kim, Se-Jin   +3 more
core   +1 more source

Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens

open access: yesNature Communications, 2016
Mucosal-associated invariant T (MAIT) cells sense riboflavin biosynthetic intermediate antigens with a semi-invariant MR1-restricted T-cell receptor (TCR). Here the authors identify a new MR1-restricted TCR that senses cells infected with S.
Erin W. Meermeier   +9 more
doaj   +1 more source

Differentiation and fiber type-specific activity of a muscle creatine kinase intronic enhancer

open access: yesSkeletal Muscle, 2011
Background Hundreds of genes, including muscle creatine kinase (MCK), are differentially expressed in fast- and slow-twitch muscle fibers, but the fiber type-specific regulatory mechanisms are not well understood. Results Modulatory region 1 (MR1) is a 1-
Tai Phillip WL   +9 more
doaj   +1 more source

Nitrogen-doped mesoporous activated carbon from Lentinus edodes residue: an optimized adsorbent for pharmaceuticals in aqueous solutions

open access: yesFrontiers in Chemistry
In this study, phosphoric acid activation was employed to synthesize nitrogen-doped mesoporous activated carbon (designated as MR1) from Lentinus edodes (shiitake mushroom) residue, while aiming to efficiently remove acetaminophen (APAP), carbamazepine ...
Bei Chu   +4 more
doaj   +1 more source

Understanding and modulating the MR1 metabolite antigen presentation pathway

open access: yes, 2020
The MHC class I-related protein, MR1, presents small metabolite antigens to an unusual subset of innate-like T cells. Herein, we highlight recent progress in our understanding of MR1’s unique antigen presenting pathway, with features of both MHC class I ...
McWilliam, Hamish EG, Salio, Mariolina
core   +1 more source

Selective inhibition of MR1-restricted T cell activation by a novel MR1-targeting nanobody

open access: yes
Abstract MR1 is a non-polymorphic, ubiquitously expressed, MHC class I-like antigen-presenting molecule that presents small-molecule metabolites to T cells. Studies have shown that MR1 plays a role in microbial infection, inflammation, and tumor immunity.
Timothy Bates   +9 more
openaire   +2 more sources

MR1-067 - Malol, Ali (wordlists)

open access: yes
A: Malol A B C_part (female consultant) B: Malol more_of_C (female consultant); Ali A (male consultant) The Malol lists correspond to the written list MR1-066-malol. There is further checking of this list on tape MR1-073-B.

core   +1 more source

Engineering of isogenic cells deficient for MR1 with a CRISPR/Cas9 lentiviral system: tools to study microbial antigen processing and presentation to human MR1-restricted T cells [PDF]

open access: yes, 2016
The nonclassical HLA molecule MHC-related protein 1 (MR1) presents metabolites of the vitamin B synthesis pathways to mucosal-associated invariant T (MAIT) cells and other MR1-restricted T cells.
Miles, John James   +13 more
core   +1 more source

Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1

open access: yesJournal for ImmunoTherapy of Cancer
Human leukocyte antigen (HLA) restriction of conventional T-cell targeting introduces complexity in generating T-cell therapy strategies for patients with cancer with diverse HLA-backgrounds.
Aimee du Chatinier   +25 more
doaj   +1 more source

Home - About - Disclaimer - Privacy